Abstract
Adriamycin is perhaps the most important chemotherapeutic agent currently available, due to its broad spectrum of activity against human solid tumors [9]. For this reason, considerable attention has been devoted to the development of other anthracycline analogues which could be more active or less toxic than adriamycin. This situation is quite similar to that which occurred in the antibiotic field after the initial discovery of penicillin. The probability that analogues of such a drug will be active is quite high, in fact. Since adriamycin itself is a second-generation anthracycline, an analogue of daunorubicin, it is apparent that small structural modifications on an anthracycline antibiotic can cause large differences in the spectrum of clinical activity. Problems arise, however, in deciding which new analogue is worthy of clinical study and the approach which should be taken to the study of such a drug.
Junior Faculty Fellow, American Cancer Society.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bachur, N. R., et al.: Tissue distribution and disposition of duanomycin (NSC 82151) in mice: Fluorometric and isotopic methods. Cancer Chemother. Rep. 54, 89 (1970)
Benjamin, R. S., et al.: Human metabolism of adriamycin (A). Proc. Am. Assoc. Cancer Res. Am. Soc. Clin. Oncol. 15, 76 (1974)
Benjamin, R. S., Keating, M. J., McCredie, K. B., Bodey, G. P., Freireich, E. J.: A phase I-II trial of rubidazone in patients with acute leukemia. Cancer Res. 37, 4623 (1977)
Benjamin, R. S., Riggs, C. E., Jr., Bachur, N. R.: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 37, 1416 (1977)
Benjamin, R. S., Valdivieso, M., Rodriguez, V., Copeland, M. M., Bodey, G. P.: A phase I-II study of rubidazone in patients with solid tumors. Proc. Am. Assoc. Cancer Res. Am. Soc. Clin. Oncol. 18, 143 (1977)
Benjamin, R. S., Mason, J. W., Billingham, M. E.: Cardiac toxicity of adriamycin-DNA complex and rubidazone: Evaluation by electrocardiogarm and endomyocardial biopsy. Cancer Treat. Rep. 62, 935 (1978)
Bristow, M. R., Mason, M. W., Billingham, M. E., Daniels, J. R.: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, cardiac catheterization. Ann. Intern. Med. 88, 168 (1978)
Carter, S. K.: Antitumor antibiotics — thoughts for the future. Recent Results Cancer Res. 63, 298 (1978)
Carter, S. K., Bachur, N. R., Benjamin, R. S., Hall, T. C.: Adriamycin: New drug seminar. Cancer Chemother. Rep. 6, 83 (1975)
Denine, E. P., Schmidt, L. M.: Adriamycin-induced myopathies in the rhesus monkey with emphasis on cardiomyopathy. Proc. Med. Soc. Toxicol. 33, 162, 197, 81 (1965)
DiMarco, A., Gaetani, M., Scarpinato, B.: Adriamycin (NSC 123127): A new antibiotic with antitumor activity. Cancer Chemother. Rep. 53, 33 (1969)
Goldin, A., Johnson, R. K.: Experimental tumor activity of adriamycin (NSC 123127). Cancer Chemother. Rep. 6, 137 (1975)
Gottlieb, J. A.: Phase I and phase II clinical trials: A critical reappraisal. In: Pharmacological basis of cancer chemotherapy. Proc. 27th Annu. Symp. Fund. Cancer Res. Baltimore: Williams and Wilkins 1975, p. [498]
Gottlieb, J. A., et al.: The role of DTIC [dimethyl triazeno imidazole carboxamide, Dacarbazine (NSC 45388)] in the chemotherapy of sarcomas. Cancer Treat. Rep. 1, 299 (1976)
Handa, K., Sato, S.: Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gann 66, 43 (1975)
Huffman, D. H., Benjamin, R. S., Bachur, N. R.: Daunorubicin metabolism in acute non-lymphocytic leukemia. Clin. Pharmacol. Ther. 13, 895 (1972)
Iwamoto, Y., et al.: Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase by adriamycin and other quinones having antitumor activity. Biochem. Biophys. Res. Commun. 58, 633 (1974)
Jaenke, R. S.: An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab. Invest. 30, 292 (1974)
Mason, J. W., Bristow, M. R., Billingham, M. E., Daniels, J. R.: Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat. Rep. 62, 857 (1978)
Meriwether, W. D., Bachur, N. R.: Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res. 32, 1137 (1972)
Silvestrini, R., DiMarco, A., DiMarco, S., Dasdia, T.: Azione della daunomycina sul metabolismo degli acidi nucleici di cellule normali e neoplastiche coltivate in vitro. Tumori 49, 399 (1963)
Von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., Muggia, F. M.: Daunomycin-induced cardiotoxicity in children and adults, a review of 110 cases. Am. J. Med. 62, 200 (1977)
Young, D. M.: Pathologic effects of adriamycin (NSC 123127) in experimental systems. Cancer Chemother. Rep. 6, 159 (1975)
Zbinden, B., Brandie, E.: Toxicologic screening of daunorubicin (NSC 82151), adriamycin (NSC 123127), and their derivatives in rats. Cancer Chemother. Rep. 59, 707 (1975)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benjamin, R.S. (1980). Clinical Strategy for Evaluation of Anthracycline Analogues. In: Carter, S.K., Sakurai, Y. (eds) New Anticancer Drugs. Recent Results in Cancer Research, vol 70. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81392-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-81392-4_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81394-8
Online ISBN: 978-3-642-81392-4
eBook Packages: Springer Book Archive